UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year enDdeecdember 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

QIAGEN N.V.’s (QGEN) fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to achieve its long-term targets. Yet, adverse macroeconomic impacts and fierce rivalry pose risks for QIAGEN’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 15.3% compared with the industry's 8.8% decline. Meanwhile, the S&P 500 composite has risen 10.6% in this time frame.The r ...

Core Insights - QIAGEN N.V. has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, enhancing its syndromic testing portfolio in the U.S. This is the second FDA clearance for a QIAstat-Dx panel in 2025, following five authorizations in the past 10 months [1][3] Company Developments - QIAGEN now holds regulatory clearances for three mini panels aimed at detecting respiratory and gastrointestinal conditions, facilitating rapid treatment decisions in outpatient settings [2] - The newly authorized panel targets bacterial infections recognized as leading causes of gastrointestinal illness, complementing existing panels that include viral detection [5] - The QIAstat-Dx Gastrointestinal Panel 2 Mini B utilizes real-time PCR technology, providing results in approximately one hour with minimal hands-on time [6] - The QIAstat-Dx system is operational in over 100 countries, with plans for further expansion, including the submission of a higher-capacity instrument for U.S. regulatory clearance [7] Market Performance - Following the announcement of the FDA clearance, QIAGEN's stock rose by 3.4%, closing at $39.88, indicating positive market sentiment towards the company [3] - QIAGEN has a market capitalization of $8.55 billion and an earnings yield of 5.8%, significantly higher than the industry average of -32.8% [4] Industry Outlook - The global gastrointestinal diagnostics market was valued at $5.1 billion in 2024 and is projected to grow at a compound annual growth rate of 4.3% through 2030, driven by increasing demand for point-of-care testing and rising incidence of gastric infections and cancers [10]

Group 1 - The article highlights the focus on Qiagen N.V. (NYSE: QGEN), a mid-cap company in the medical diagnostic industry with a market capitalization exceeding $8 billion [2] - Qiagen is noted for receiving relatively little coverage in the United States, which may be attributed to its headquarters location [2] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2]

QIAGEN N.V.’s (QGEN)  fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange rate (CER). The reported figure increased 11% from the 2023 comparable figure. However, it fell short of the Zacks Consensus Estimate by 1.6%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortiza ...

Financial Data and Key Metrics Changes - Net sales for Q4 2024 were €521 million, growing 3% at constant exchange rates (CER), surpassing the outlook of at least €520 million CER [11] - Adjusted diluted EPS was $0.61 at CER, exceeding the target of at least $0.60 CER [12] - For the full year 2024, net sales exceeded the outlook of at least €1.985 billion CER, and adjusted EPS reached $2.20 CER compared to the initial target of $2.10 CER [12][43] - Adjusted operating income margin rose by 2.6 percentage points to 30.6% in Q4 2024, with a full-year margin of 28.7%, an increase of 1.8 percentage points from 2023 [17][41] Business Line Data and Key Metrics Changes - KIAstat Diagnostics experienced 25% CER growth in Q4 2024, with over 616 new system placements in 2024 [13] - QuantiFERON, the test for latent tuberculosis, delivered 14% growth in Q4 and 11% growth for the year, indicating strong adoption [14] - Digital PCR sales grew 3% CER, driven by consumables for the QIAcuity system, which saw over 2,700 placements since launch [30] - Sample Technologies saw a slight decline in Q4 2024, with a full-year decline of 3% CER, but is expected to swing to low single-digit growth in 2025 [26] Market Data and Key Metrics Changes - In the EMEA region, sales rose 4% CER, with strong performance in France, Italy, Spain, and Switzerland [35] - The Americas region saw a 5% CER increase, with solid growth in the US, Canada, Brazil, and Mexico [35] - Asia Pacific Japan region sales declined 5% CER in Q4, with a full-year decline of 7% CER, particularly impacted by a low teens decline in China [35] Company Strategy and Development Direction - The company aims for a 7% sales CAGR from 2024 to 2028, with a target of at least $1 billion in returns to shareholders by the end of 2028 [22] - Plans to launch three new sample tech systems by the end of 2026 to enhance growth [49][102] - Focus on expanding the QuantiFERON market share and increasing access to testing for latent tuberculosis [50][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 5% growth in core business for 2025, despite a cautious macroeconomic environment [89] - The company anticipates a gradual recovery in capital spending in labs starting in H2 2025 [90] - Management highlighted the solid fundamentals in the diagnostic and research markets, driven by aging populations and technological advancements [88] Other Important Information - Free cash flow for 2024 was €506 million, up 63% compared to 2023 [18] - The company completed a synthetic share repurchase of approximately $300 million, reaffirming its commitment to return capital to shareholders [19] Q&A Session Summary Question: QuantiFERON growth and patent win implications - Management confirmed expectations for low double-digit growth in QuantiFERON for 2025 and highlighted strong IP protection [76][78] Question: Market conditions and instrument spending outlook - Management acknowledged a cautious capital expense environment but expects normalization starting in H2 2025 [90][91] Question: Margin expansion potential - Management indicated that margin improvements are driven by efficiency projects and the discontinuation of Numodix, with potential for further increases beyond 2025 [92][94] Question: Sample Technologies growth outlook - Management emphasized ongoing investment in automated sample technologies and plans for new instrument launches to drive future growth [100][102] Question: Growth assumptions by end market - Management believes in solid market fundamentals and anticipates a gradual recovery in capital sales, projecting 4-5% market growth [110][112]

Q4 and FY 2024 results Exceeding outlook for net sales and adjusted EPS February 5, 2025 Forward looking and intended use statements Safe Harbor Statement: Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory ap ...

Company Performance - Qiagen reported quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.62 per share, but showing an increase from $0.57 per share a year ago, resulting in an earnings surprise of -1.61% [1] - The company posted revenues of $521.2 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.09% and increasing from $509.16 million year-over-year [2] - Over the last four quarters, Qiagen has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Qiagen shares have underperformed the market, losing about 5.3% since the beginning of the year compared to the S&P 500's gain of 2.7% [3] - The current consensus EPS estimate for the coming quarter is $0.52 on revenues of $479.38 million, and for the current fiscal year, it is $2.34 on revenues of $2.08 billion [7] - The estimate revisions trend for Qiagen is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Qiagen belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - QIAGEN N.V. focuses on partnerships for product development and sees significant opportunities in next-generation sequencing (NGS) for precision medicine [1] - The company has a market capitalization of $10.30 billion and has experienced a 2.3% decline in stock value over the past year, compared to an 11.3% decrease in the industry [2] - QIAGEN's earnings have surpassed estimates in three of the last four quarters, with an average surprise of 3.5% [2] Strategic Collaborations - In September 2024, QIAGEN announced a collaboration with Eli Lilly to develop a QIAstat-Dx in-vitro diagnostic for detecting APOE genotypes related to Alzheimer's disease [3] - The company has partnered with Bode Technology for the GEDmatch PRO genealogy database to assist forensic investigations [3] - QIAGEN extended its partnership with Bio-Manguinhos/Fiocruz to enhance malaria and dengue detection in Brazil [4] - A collaboration with AstraZeneca aims to develop and commercialize companion diagnostics in chronic diseases [4] - QIAGEN is working with Myriad Genetics to create a globally distributable kit-based test for analyzing Homologous Recombination Deficiency [4] NGS Platform Prospects - QIAGEN is one of the top three providers of human identification solutions and has expanded into NGS applications, with its Genomics/NGS portfolio showing robust revenue growth [5] - The company has partnered with Element Biosciences to offer NGS workflows on their AVITI System, aligning with its strategy for platform-agnostic solutions [6] - QIAGEN introduced a new version of clinical decision support software, QIAGEN Clinical Insight Interpret, enhancing performance for high-throughput NGS labs [6] Test Menu Expansion - QIAGEN invests heavily in R&D for expanding its product menu, with the QIAstat-Dx systems receiving CE-marking under new EU regulations [7] - The company has added 100 new validated assays in areas such as cancer research and infectious disease surveillance [9] - Following FDA approval, QIAGEN has begun placements of the QIAcuityDx system, focusing initially on oncology, and aims to exceed a sales target of at least $100 million in 2024 [10] Market Challenges - QIAGEN faces macroeconomic risks affecting global sales, including political and economic instability in emerging markets [11] - The company is experiencing competitive pressures from firms offering similar pre-analytical solutions, making customer retention challenging [12] Financial Estimates - The Zacks Consensus Estimate for QIAGEN's 2024 earnings per share is $2.18, with revenues projected at $1.98 billion, indicating a 0.6% increase from the previous year [13]

Company Overview - Qiagen (QGEN) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.60, reflecting a +9.1% change, and revenues of $520.73 million, up 2.3% from the previous year [3][10] - The earnings report is scheduled for February 5, 2025, and the actual results will significantly influence the stock price depending on whether they meet or exceed expectations [2][3] Earnings Estimates and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for Qiagen is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.76%, suggesting a bullish outlook from analysts [10][11] - Historical performance shows that Qiagen has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.56% [12][13] Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, Amgen (AMGN) is also expected to report positive results, with an EPS of $5.01, indicating a +6.4% year-over-year change, and revenues of $8.84 billion, up 7.9% [17] - Amgen's consensus EPS estimate has been revised slightly lower, but a higher Most Accurate Estimate has resulted in an Earnings ESP of +3.15%, suggesting a likely earnings beat [18]